Cannabis
U.S. Drug Enforcement Agency to Expand Cannabis Research: GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana Researchers
GB Sciences, Inc. (OTCQB: GBLX) today announced that it has received notification from the U.S. Drug Enforcement Agency (DEA) that prior to making any decisions on the pending applications, the DEA intends to distribute regulations that govern the program of growing marijuana for scientific research under DEA registration. GB Sciences is one of just 33 companies that applied to the DEA to become registered under the Controlled Substances Act (CSA) to grow (manufacture) marijuana in order to supply DEA-registered researchers in the United States. Last week, after a three-year delay and following pressure by Congress, patients and researchers, the DEA announced that it will move forward with creating revised regulations and with reviewing the applications.
“We are well-positioned to meet and exceed the DEA’s criteria, and we intend to aggressively pursue federal licensure,” said Dr. Andrea Small-Howard, Chief Science Officer and Director of GB Sciences. “The sophistication of our facilities, our team’s deep scientific experience, and our groundbreaking cannabinoid therapies are unparalleled inthe United States.”
According to the letter from the DEA, it is looking to facilitate research, advance scientific understanding about the effects of marijuana, and potentially aid in the development of safe and effective drug products that may be approved for marketing by the Food and Drug Administration.
GB Sciences’ 28,000-square-foot facility in Las Vegas, Nevada features one of the only pharmaceutical-grade “cleanroom-type” grows in the United States. The company’s groundbreaking research program, led by Dr. Small-Howard with nine university research partners in the U.S. and internationally, has created a patent portfolio of cannabis-based therapies that cover over 60 disease and health conditions including Parkinson’s disease, neuropathic pain, and cardiac hypertrophy.
Cannabis
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
Cannabis
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Innocan2 weeks ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf2 weeks ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis2 weeks ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
Cannabis5 days ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
SCHWAZZE6 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis5 days ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Humboldt5 days ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
Cannabis3 days ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III